Norprolac (Quinagolide)

Quinagolide selectively stimulates dopamine D2 receptors on pituitary lactotroph cells. This activation suppresses adenylate cyclase activity, reduces cyclic AMP formation, and consequently inhibits the synthesis and release of prolactin, restoring normal hormonal balance.

The dose of Norprolac is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Healthcare professionals determine the appropriate starting dose and any subsequent adjustments; patients should follow the prescriber’s instructions precisely.

Safety data for quinagolide during pregnancy and lactation are limited. Because the drug can affect prolactin, which is important for lactation, it is generally avoided unless the potential benefit outweighs the risk. Physicians should evaluate each case carefully.

To request Norprolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to quinagolide is cabergoline, another dopamine agonist. Cabergoline has a longer half‑life and is often dosed less frequently, while quinagolide may be preferred when a shorter‑acting agent is desired. Both agents lower prolactin, but their side‑effect profiles and dosing schedules differ.

Norprolac tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Norprolac is taken orally, usually with a glass of water. It is typically administered once daily, but the exact timing and whether it should be taken with food are determined by the prescribing physician.

Serious adverse events include valvular heart disease, pulmonary hypertension, severe depression, and cardiac arrhythmias. Patients should report any new chest discomfort, shortness of breath, mood changes, or irregular heartbeats to their healthcare provider promptly.

Norprolac is contraindicated in individuals with known hypersensitivity to quinagolide, uncontrolled hypertension, or pre‑existing severe cardiac valve disease. Caution is also advised for patients with a history of psychiatric disorders or those taking medications that strongly inhibit CYP3A4.